title: Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.
abstract: (E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells. Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP). Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression. 3-Cl-AHPC analogues having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis. Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity. Docking of 3-Cl-AHPC and its analogues to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity. Inhibitory activity against Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp-2) was also assessed. The most active Shp-2 inhibitor was found to be the 3'-(3,3-dimethylbutynyl) analogue of 3-Cl-AHPC.
authors.affiliation: Cancer Center and Inflammatory and Infectious Disease Center, Burnham Institute for Medical Research, La Jolla, California 92037, USA. mdawson@burnham.org
authors.forename: Marcia I
authors.initials: MI
authors.lastname: Dawson
authors.forename: Zebin
authors.initials: Z
authors.lastname: Xia
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.forename: Mao
authors.initials: M
authors.lastname: Ye
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Fontana
authors.forename: Lulu
authors.initials: L
authors.lastname: Farhana
authors.forename: Bhaumik
authors.initials: B
authors.lastname: Patel
authors.forename: Li Ping
authors.initials: LP
authors.lastname: Xue
authors.forename: Mohammad
authors.initials: M
authors.lastname: Bhuiyan
authors.forename: Roberto
authors.initials: R
authors.lastname: Pellicciari
authors.forename: Antonio
authors.initials: A
authors.lastname: Macchiarulo
authors.forename: Roberto
authors.initials: R
authors.lastname: Nuti
authors.forename: Xiao-Kun
authors.initials: XK
authors.lastname: Zhang
authors.forename: Young-Hoon
authors.initials: YH
authors.lastname: Han
authors.forename: Lutz
authors.initials: L
authors.lastname: Tautz
authors.forename: Peter D
authors.initials: PD
authors.lastname: Hobbs
authors.forename: Ling
authors.initials: L
authors.lastname: Jong
authors.forename: Nahid
authors.initials: N
authors.lastname: Waleh
authors.forename: Wan-Ru
authors.initials: WR
authors.lastname: Chao
authors.forename: Gen-Sheng
authors.initials: GS
authors.lastname: Feng
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Pang
authors.forename: Ying
authors.initials: Y
authors.lastname: Su